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ABSTRACT Reactive oxygen species play an important
role in the pathogenesis of diabetic retinopathy. We
studied the role of adrenergic and serotonin receptors in
the generation of superoxide by retina and 661W retinal
cells in high glucose and of the a1-adrenergic receptor
(AR) on vascular lesions of the retinopathy in experi-
mentally diabetic C57Bl/6J mice (and controls) after 2
and 8 months. Compared with 5 mM glucose, incubating
cells or retinal explants in 30 mM glucose induced super-
oxide generation. This response was reduced or ablated
by pharmacologic inhibition of the a1-AR (a Gq-coupled
receptor) or Gs-coupled serotonin (5-HT2, 5-HT4, 5-HT6,
and5-HT7) receptorsorby activationof theGi-coupleda2-
AR. In elevated glucose, the a1-AR produced superoxide
via phospholipase C, inositol triphosphate-induced Ca2+
release, and NADPH oxidase, and pharmacologic in-
hibition of these reactions prevented the superoxide in-
crease. Generation of retinal superoxide, expression of
proinﬂammatory proteins, and degeneration of retinal
capillaries in diabetes all were signiﬁcantly inhibited with
daily doxazosin or apocynin (inhibitors of a1-AR and
NADPH oxidase, respectively), but increased vascular
permeability was not signiﬁcantly affected. Adrenergic
receptors, and perhaps other GPCRs, represent novel
targets for inhibiting the development of important fea-
tures of diabetic retinopathy.—Du, Y., Cramer, M., Lee,
C. A., Tang, J., Muthusamy, A., Antonetti, D. A., Jin, H.,
Palczewski, K., Kern, T. S. Adrenergic and serotonin
receptors affect retinal superoxide generation in diabetic
mice: relationship to capillary degeneration and perme-
ability. FASEB J. 29, 2194–2204 (2015). www.fasebj.org
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GPCRS FORM A LARGE DIVERSE superfamily of membrane
proteins encoded by .800 genes in the human genome
(1). They detect a wide spectrum of extracellular signals,
including photons, ions, small organic molecules, and
proteins before undergoing conformational changes that
cause activation of cytosolic signaling through activation of
G proteins, including the subtypes Gs, Gi, and Gq (2). Sig-
nalingpathways regulatedby theseGproteins thenregulate
effector molecules such as calcium, potassium channels,
adenylate cyclase, phospholipase C (PLC), and protein
kinases. Rhodopsin is probably the best-recognized GPCR
that is expressed in retinal cells, butnumerousotherGPCRs
also are involved in maintaining retinal function and in-
tegrity (3). GPCRs also can contribute to retinal diseases.
They have been implicated in the generation of reactive
oxygen species, in part via regulation of intracellular cal-
ciumandNADPHoxidase ina varietyofcell types, including
retinal photoreceptor cells undergoing light-induced reti-
nal degeneration (3–5).
Diabetes is known to induce oxidative stress in multiple
tissues including the retina. Characteristic lesions of di-
abetic retinopathy in animals have been inhibited with oral
antioxidants or overexpression of antioxidant enzymes
(6–8), indicating that oxidative stress plays an important
role in diabetes-induced retinalmicroangiopathy. Recently
we showed that retinalphotoreceptorcells generatemostof
the diabetes-induced increase in retinal generation of su-
peroxide viamitochondria and NADPH oxidase (9).
Here we investigated the contribution of several GPCRs
and their downstream signaling pathways to superoxide
generation by retina and retinal cells. We focused initially
on adrenergic receptors (ARs) and 5-hydroxytryptamine
(serotonin) receptors (HTRs) because these receptors
were identiﬁed in retinas from multiple species by tran-
scriptome analysis (3), and HTR agonists were shown by
others to inhibit retinal degenerative diseases (10–14).
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Although these receptors had not been previously im-
plicated in diabetic retinopathy, our present ﬁndings
demonstrate that pharmacologic manipulation of these
receptors canregulate superoxidegenerationbyretinasand
retinal cells exposed to elevated glucose. Moreover, phar-
macologic inhibition of either the a1-AR or downstream
NADPH oxidase (both components of the Gq-regulated
signaling pathway) lowered the diabetes-induced increase
in retinal oxidative stress, expression of proinﬂammatory
proteins by the retina, and the resulting degeneration of
retinal capillaries. These results identify GPCRs and their
downstream pathways as novel therapeutic targets that can
reduce retinal superoxide generation and the histopathol-
ogy of diabetic retinopathy.
MATERIALS AND METHODS
Chemicals
Doxazosin (Dox), apocynin (Apo),U73122, 2-aminoethoxydiphenyl
borate (2-APB), ruthenium red, guanabenz (Gub), and
brimonidine (Brim) were obtained from Sigma Chemicals
(St. Louis, MO, USA). Lofexidine (Lof) was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). LY 215840, RO 04-
6790, RS 23597-190, and SQ 22536 were purchased from
TOCRIS Biosciences (Bristol, United Kingdom). Sp-5,6-dichloro-
1-b-D-ribofuranosylbenzimidazole-39,59-monophosphorothioate,
dibutyryl cAMP, isobutylmethylxanthine, 1-methyl-3-isobutylxanthine
(IBMX), and KT5720 were obtained from Enzo Life Sciences
(Farmingdale, NY, USA).
In vitro studies
For initial drug candidate screening, we used a well-studied trans-
formed cell line (661W) of retinal cells (15). The identity of these
cells was conﬁrmed by the positive identiﬁcation of cone opsin
mRNA and other proteins previously identiﬁed in this cell line
(Supplemental Fig. S1). These cells were passaged in DMEMme-
dium containing 5 mM glucose and 10% fetal bovine serum. For
experiments, the fetal serum was reduced to 2%, and cells were
incubated in either 5 or 30 mM glucose for 4 days with medium
changedevery other day. Test agents were added to themediumat
2–3 concentrations, each based on published reports as summa-
rized in Table 1, with DMSO used as a control. Test drug con-
centrations that best reduced superoxide generation are shown in
theﬁgures.Cellswereharvestedbyaddinga trypsin-EDTAsolution
(0.5%and0.02%,w/v) to theculture followedbycentrifugation. In
some experiments, Dox and Gub or Dox and RO 04-6790 were
concurrently administeredat suboptimaldoses for4days.Effectsof
optimal concentrations of these drugs (selected for their ability to
inhibit superoxide generation in 30 mM glucose) on cell death
after 4 days are shown in Supplemental Table S1.
Retinal explants
Eyes were enucleated from adult C57Bl/6J mice and immediately
immersed in ice-cold DMEM containing 10% fetal bovine serum,
penicillin (100 U/ml), and streptomycin (100 mg/ml). The pos-
terior pole (including retina, retinal pigment epithelium, and
sclera) was incubated for 4 days in DMEM in humidiﬁed incuba-
tors with 5% CO2 at 37°C, thus keeping the retina in contact with
the retinal pigmented epithelium. The culture medium was
changed every other day. At the end of this incubation, the retina
was separated from the retinal pigment epithelium prior to the
assay for superoxide.
Animals
All experiments followed the guidelines set forth by the Associa-
tion for Research in Vision and Ophthalmology Resolution on
Treatment of Animals in Research and the Institutional Animal
Care and Use Committee at Case Western Reserve University.
Insulin-deﬁcientdiabeteswas induced in2-month-old fastedmale
C57BI/6J mice by intraperitoneal injections of streptozotocin
[55mg/kg body weight (BW)] on 5 consecutive days. Insulin was
givenasneeded(0–0.2units every 2–3days) tomaintainBWwhile
allowing chronic hyperglycemia, polyuria, and hyperphagia.
Blood glucose and hemoglobin A1c (HbA1c) were measured as
reported previously (16, 17). All therapeutics were administered
by intraperitoneal injection inDMSO.Diabetic and age-matched
nondiabetic controls were studied after 2 durations of diabetes
(2 and 8 months).
Drugs administered in vivo
Diabetic mice were treated with (i) the a1-AR antagonist, Dox
(10 mg/kg BW, daily intraperitoneal injection in DMSO); (ii)
the NADPH oxidase inhibitor, Apo (36 mg/kg BW; daily in-
traperitoneal injection in DMSO); (iii) the PLC inhibitor, U73122
(6.25 mg/kg BW; daily intraperitoneal injection in DMSO; or (iv)
the calcium channel inhibitor, 2-APB (6.25 mg/kg BW; daily in-
traperitoneal injection inDMSO). Thea2-AR agonist, Lof, also was
given to animals (dose initially was 2 mg/kg BW daily via in-
traperitoneal injection in DMSO). Doses were selected based on
prior publications (5) or initial dosing studies (data not shown). In
all the above experiments, DMSO was injected intraperitoneally as
the vehicle control.
Superoxide generation
Retinas or isolated cells were incubated in 200 ml of Krebs-[4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid buffer, pH 7.2,
with 5 or 25 mM glucose for 5 minutes at 37°C in 5% CO2.
Luminescence indicating the presence of superoxide was mea-
sured 5 minutes after addition of 0.54 mM (ﬁnal concentration)
lucigenin, as published previously (18–22). Luminescence in-
tensity is reported in arbitrary units per milligram protein.
To conﬁrm the results obtained by the lucigenin method, we
also measured reactive oxygen species with a 29,79 dichloro-
ﬂuorescein acetate method previously reported by Best et al.
(23). Results obtainedwith this alternatemethodwere consistent
with those found with lucigenin (data not shown).
Intracellular cAMP assay
Cells (661W) were incubated with either 5 mM glucose, 30 mM
glucose, or 30 mM glucose containing drugs at their indicated
concentrations for 4 days. Intracellular cAMP levels were mea-
sured with the cAMP Biotrak Enzyme Immunoassay System (GE
Healthcare Life Sciences, Piscataway, NJ, USA). To ensure equal
protein concentrations, cell numbers in each sample were de-
termined, and the volumeof lysis buffer was adjusted accordingly.
Isobutylmethylxanthine (1mM)was included in the lysis buffer to
inhibit cAMP-dependent phosphodiesterase activity.
Immunoblots
Retinal homogenates were separated by SDS-PAGE and in-
cubated with either anti-rat intercellular adhesion molecule-1
(1:2000dilution;R&DSystems,Minneapolis,MN,USA)or theanti-
inducible isoform of nitric oxide synthase (iNOS; 1:1000 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA, USA). Protein levels
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were quantiﬁed relative to b-actin loading controls (1:3000 di-
lution; Abcam, Cambridge, MA, USA) in the same samples.
RT-PCR
To conﬁrm that 661W cells were from photoreceptor cells, we
used PCR for red/green opsin. Methods and results are sum-
marized in the Supplemental Material.
Permeability
Retinal permeability wasmeasured in eyes from animals that were
diabetic for 8 months and their age-matched controls by using
aﬂuorescently labeled tracer as described previously (24). Brieﬂy,
sterileFITC-bovine serumalbumin(BSA;50mg/ml) inPBS(NaCl,
0.138 M; KCl, 0.0027 M; pH 7.4) was injected into the tail vein of
mice at 100 mg/g BW. The dye circulated for 20 minutes before
blood sampleswere collected andeyeswere enucleated. Eyeswere
ﬁxed in ice cold 4% paraformaldehyde, infused with sucrose, and
then frozen in optimal cutting temperature compound in iso-
pentane on dry ice. Retinal cryosections were imaged by ﬂuores-
cence microscopy. Two images per eye were obtained on either
side of the optic disc in the inner plexiform layer, and 2 sections
per eyewere imaged to generate an average imagepixel density in
the neural retina exclusive of any vessels. Relative average value
ﬂuorescence increases were normalized to the relative plasma
ﬂuorescence forﬁnal determinations of retinal dye accumulation.
Because diabetes can increase glycation and other processes that
cause autoﬂuorescence and thus might confound interpretation
of ﬂuorescence data after injection of FITC-BSA, preliminary
studies of retinal sections after long-termdiabeteswere carriedout
to evaluate possible autoﬂuorescence. Our methods failed to de-
tect an increase in autoﬂuorescence (ﬂuorescence in the FITC
channel in the absence of FITC-BSA) caused by diabetes, so no
correction of the permeability data was made.
Diabetes-induced retinal histopathology
After 8months of diabetes, 1 retina fromeachmouse was isolated
for assessment of capillary histopathology, as describedpreviously
(25–27). Brieﬂy, formalin-ﬁxed retina was digested with 40U/ml
elastase (Calbiochem, SanDiego, CA, USA) for 2–3 hours. When
totally freed of neural cells, the isolated retinal vasculature was
laid out on a glass microscope slide, dried, and stained with he-
matoxylin and periodic acid-Schiff. Degenerated (acellular)
capillaries (Supplemental Fig. S2) were quantiﬁed in a masked
manner in 6–7 ﬁeld areas corresponding to the midretina. To
evaluate possible photoreceptor degeneration in the long-term
studies, the other eye was sectioned, and the number of cells in
the outer nuclear layer from 2 areas on either side of the optic
nerve (;300 mm from the optic nerve) was counted, and the 4
resulting values were averaged together to compute a single es-
timate for each animal.
Visual function
Spatial frequency threshold and contrast sensitivity were mea-
sured after 2 and 8 months of diabetes as previously described
(16), except that at 2 months, only a single spatial frequency
(0.064 c/d)wasmeasured.Thegraderwasmaskedwith respect to
the animals’ experimental group. Although nondiabetic mice
could be differentiated from diabetic animals based on BW,
investigators could not discern group identity because some dia-
betics were treated with agents, whereas others were not.
Statistical analyses
Data are expressed asmeans6 SD except for the permeability
and contrast sensitivity studies, where data are expressed as
means6 SEM. All statistical analyses were performed with ANOVA,
followedbyFisher’s test, except for the full contrast sensitivity curve.
The latter was analyzed by repeated-measures ANOVA to account
for the testingofeachanimal atmultiple spatial frequencies.Values
of P, 0.05 were considered statistically signiﬁcant.
RESULTS
In vitro studies
In vitro studies were done to evaluate the contribution of
Gs-, Gi-, and Gq-mediated GPCR signaling pathways to the
TABLE 1. Agents affecting signaling pathways studied in vitro
Agent Mode of action Signaling In vitro doses (mM)
Doxazosin (Dox) a1-AR antagonist Gq 10, 100, 1000
Phenoxybenzamine (PBA) a-AR antagonist Gq 10, 20
Prazosin (PRA) a1-AR antagonist Gq 0.5, 5
U73122 PLC inhibitor — 1, 5, 10
2-APB IP3 receptor inhibitor — 10, 100, 200
Ruthenium red (RR) Calcium release from ER inhibitor — 5, 10
Apocynin (Apo) NADPH oxidase inhibitor — 10, 100, 1000
Lofexidine (Lof) a2-AR agonist Gi 10, 100, 1000
Guanabenz (Gub) a2-AR agonist Gi 1, 10
Brimonidine (Brim) a2-AR agonist Gi 1, 10
LY 215840 (LY) 5-HT2R/5-HT7R antagonist Gs, Gq 10, 100
RO 04-6790 (RO) 5-HT6 R antagonist Gs 10, 100
RS 23597-190 (RS) 5-HT4R antagonist Gs 10, 100
Dibutyryl cAMP (db cAMP) Adenylate cyclase agonist Gs 200, 500, 1000
sp-5,6-DCI-cBIMPS cAMP analog, PKA activator Gs 1, 10, 50
SQ 22536 (SQ) Adenylate cyclase antagonist Gs 50, 500
IBMX Phosphodiesterase inhibitor Gs 30, 100, 225
KT5720 PKA inhibitor Gs 0.05, 2
Forskolin Adenylate cyclase agonist Gs 10
Assays performed in vitro with 661W cells are described in the Materials and Methods section.
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increase in superoxidegenerationby 661Wcells incubated
in diabetes-like (30 mM) concentrations of glucose. The
identities of agonists and antagonists of AR and 5-HT path-
ways used for these studies are summarized in Fig. 1 and
Table 1. Selection of this cell line for the in vitro studies was
solely because it is awell-studied cell linederived fromretinal
cells; results from these studies do not speciﬁcally implicate
cones in the pathology of diabetic retinopathy.
Gq-mediated signaling is known to activate NADPH
oxidase (5), making this signaling pathway of special in-
terest as a potential contributor to the generation of su-
peroxide during elevated glucose concentrations and
diabetes. Pharmacologic inhibition of the a1-AR with
either Dox, PBA, or PRA (Fig. 2) signiﬁcantly inhibited
glucose-induced generation of superoxide by 661W cells.
Because the a1-AR is known to regulate the activity of
NADPH oxidase via activation of PLC, generation of ino-
sitol triphosphate (IP3), and calcium release from the
endoplasmic reticulum (ER), we pharmacologically in-
hibited each of these steps in vitro (Fig. 2).
Pharmacologic inhibition of PLC by U73122, IP3
receptors with 2-APB, calcium release from the ER by
ruthenium red, or NADPH oxidase with Apo also signif-
icantly inhibited the glucose-induced increase in super-
oxide generation by these cells. a1-AR signaling has not
been found to affect cAMP, and consistent with this ob-
servation, Dox did not inhibit the glucose-induced in-
crease in cAMP (Fig. 3).
Activation of the Gs pathway leads to accumulation of
cAMP. In addition to b-ARs, several 5-HTRs, including
5-HT4Rand5-HT7R,areknown to signalvia theGspathway.
The cAMP mimic, dibutyryl cAMP, and the phosphodies-
terase inhibitor, IBMX, both increased the generation of
superoxide in vitro. Inhibition of signaling with the 5-HT2/
5-HT7Rantagonist, LY215840,orantagonistsof the5-HT6R
(RO 04-6790) or 5-HT4R (RS 23597-190) signiﬁcantly
inhibited superoxide production by 661W cells in high
glucose, as did the adenylate cyclase inhibitor, SQ 22536.
The most effective doses tested in vitro are summarized
in Fig. 4. These results demonstrate that elevating cAMP
levels increased the production of superoxide in hypergly-
cemia in a retinal cell culture system. Because the effects
of cAMP accumulation are often mediated via cAMP-
dependent protein kinase (PKA), we tested the effect of
PKA inhibition byKT5720 on superoxide generation.Here
we found that PKA inhibition did not decrease superoxide
production, but instead signiﬁcantly increased it (Fig. 4),
suggesting that superoxide generation by retinal cells in
high glucose does not require PKA signaling.
Activation of Gi-mediated signaling is known to inhibit
adenylate cyclase. Consistent with this observation, acti-
vation of a2-AR signaling by Gub signiﬁcantly inhibited
cAMP generation in high glucose (Fig. 3). Thus, we tested
whether stimulation of a2-AR signaling would also inhibit
superoxide generation in high glucose. As shown in Fig. 5,
several agonists of the a2-AR (Lof, Gub, and Brim) did
Figure 1. Postulated relationships of major GPCR signaling pathways (Gs, Gi, and Gq) to superoxide generation and drugs used in
vitro to test these relationships.
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indeed signiﬁcantly inhibit superoxide generation by
661W cells in 30 mM glucose.
To further investigate the impactofG-coupled signaling
pathways on superoxide generation by retinal cells in high
glucose, we tested whether suboptimal doses of thera-
peutics that affected different G protein signaling path-
ways would have additive effects on superoxide inhibition
(Fig. 6). Simultaneous inhibition of 5-HTRs (that signal
through the Gs pathway) and a1-AR (Gq pathway) with
suboptimal doses of Dox and RO 04-6790 caused signiﬁ-
cantly greater inhibition of superoxide generation than
either drug alone (Fig. 6). Simultaneous activation of the
Gi- and inhibition of Gq-mediated signaling pathways with
suboptimal doses of Dox and Gub showed less than an
additive inhibitory effect.
Retinal explants
Incubation of retinal explants in 30 mM glucose for 4 days
resulted in a signiﬁcant increase in superoxide generation
compared with their incubation in 5 mM glucose (Fig. 7).
This increase was signiﬁcantly inhibited by either Dox,
Gub, or RO and was marginally increased by the PKA in-
hibitor, KT5720. These results were very consistent those
obtained with 661W cells, again indicating that the cAMP-
driven increase in superoxide was not mediated via PKA.
In vivo studies
Based on our encouraging in vitro screening results, we
proceeded to in vivo studies focusing initially on thea1- and
a2-ARs known to be prevalent in the retina (3). Dox was
used to inhibit thea1-ARs, andLofwasusedasanagonist for
the a2-ARs. Both compounds were administered daily for
2 months, starting promptly after the initiation of diabetes.
Lof (initial dailydoseof2mg/kgBW)was toxic toanumber
of diabetic animals, so was not studied further in vivo.
Diabetic mice from all experimental groups in the
long-term experiment had levels of HbA1c and blood
glucose that were signiﬁcantly greater (P , 0.05) than
levels found in age-matched nondiabetic controls. Aver-
age BWs and nonfasting glucose andHbA1c levels for the
animal groups in the 8-month experiment are summa-
rized in Table 2. Clinical data for diabetic groups studied
for 2months were similar. All mice appeared healthy and
none had lost BW, although diabetic mice did not gain
weight at a normal rate.
Figure 2. Pharmacological inhibition of the a1-AR and Gq
pathway (including downstream PLC, IP3, Ca
2+, and NADPH
oxidase) decreased superoxide formation in 661W cells. Cells
were incubated for 4 days in 30 mM glucose in the presence of
therapies at the concentrations listed. Then cells were harvested,
concentrated by centrifugation, and assayed for superoxide by
the lucigenin method. Dox, PBA (phenoxybenzamine), and
PRA (prazosin) are a1-AR antagonists. Other drugs tested were
U73122 (a PLC inhibitor); APB, (2-APB or 2-aminoethoxydi-
phenyl borate, an inhibitor of IP3-induced Ca
2+ release); RR
(ruthenium red, a Ca2+ release inhibitor); and Apo (apocynin,
a NADPH oxidase inhibitor). n $ 3 for all groups.
Figure 3. Effects of inhibitors of a1-ARs or serotonin receptors
(5-HTRs), or activators of a2-ARs on cAMP levels in 661W
cells. Studies were performed as described in the legend for
Fig. 2. In some cases, drugs were combined for the full 4 days
of study. Fo (forskolin) activates adenylyl cyclase and thus
increases intracellular levels of cAMP. RO (RO 04-6790) is
a 5-HT6R antagonist. n = 3 for all groups, except n = 2 for RO
and Fo groups.
Figure 4. Pharmacologic inhibition of Gs-coupled 5-HTRs
lowered superoxide formation in 661W cells incubated for
4 days in 30 mM glucose, whereas a cAMP analog (db cAMP,
dibutyryl cAMP), a phosphodiesterase inhibitor (IBMX), or
a PKA inhibitor (KT5720) increased it. SQ, SQ 22536, an
adenylate cyclase inhibitor; LY, LY 215840, a 5-HT2R/5-HT7R
antagonist; RO, RO 04-6790, a 5-HT6R antagonist; RS, RS
23597-190, a 5-HT4R antagonist. Studies were performed as
described in the legend for Fig. 2. n $ 3 for all groups.
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In the 2-month studies, administration of Dox signiﬁ-
cantly suppressed the diabetes-induced increase in reti-
nal superoxide generation (Fig. 8). Similar to our in vitro
studies, the signaling mechanism by which the a1-AR
initiated retinal superoxide generation in diabetes also
was studied in vivo. As shown in Fig. 8, inhibition of a1-
ARs, PLC, IP3 receptors, or NADPH oxidase each signif-
icantly reduced superoxide generation by retinas from
diabetic mice.
To determine whether Gq-mediated signaling pathways
are involved in the long-termvascularpathologyofdiabetic
retinopathy, we administeredDox or Apo to diabetic mice
daily for 8 months. As expected, diabetes caused a signiﬁ-
cant increase in the number of degenerated retinal capil-
laries, leakage of FITC-BSA in the neural retina, and
a signiﬁcant impairment of visual function compared with
age-matched nondiabetic controls (Figs. 9 and 10). The
number of degenerated capillaries was signiﬁcantly re-
duced in diabetic mice treated with either Dox or Apo, as
was the retinal generation of superoxide and expression of
proinﬂammatory proteins (Fig. 9A, B). These studies
clearly implicate the a1-AR signaling pathway in the oxi-
dative stress affecting mouse retina in diabetes and show
that Dox and Apo are valid pharmacologic agents capable
of suppressing diabetic vascular degeneration. In contrast
to the beneﬁcial effect of both Dox and Apo on diabetes-
induced degeneration of retinal capillaries recorded at
8 months, neither therapy had a signiﬁcant beneﬁcial ef-
fect on the accumulation of FITC-albumin into the neural
retina (aparameterof vascular leakage) (Fig. 10).Doxhad
a statistically signiﬁcant effect on contrast sensitivity, but
neither Dox nor Apo showed a beneﬁcial effect on the
spatial frequency threshold or maintained contrast sensi-
tivity at normal levels (Fig. 9;Table 3). Neither diabetes of
8 months duration nor any tested therapeutic produced
a loss of photoreceptor cells (Table 4), and diabetic con-
trols actually had more photoreceptors than did age-
matched normal mice.
DISCUSSION
Reactive oxygen species are important in the pathogenesis
of the vascular histopathology known as diabetic reti-
nopathy (6–8). The diabetes-induced increase in retinal
generation of superoxide has been attributed to several
intracellular molecular sources, including mitochondria
(7–9), NADPH oxidase (9, 28), and pathways regulated by
iNOS (29), arginase (30), and aldose reductase (31).
In the present study, we investigated the possibility that
some extracellular GPCRs contribute to superoxide gener-
ationby the retina indiabetes.Whenbinding toappropriate
ligands, GPCRs transduce extracellular stimuli into in-
tracellular second messengers through activation of one or
several G proteins, including the Gs, Gi, and Gq subtypes.
Previous studies have demonstrated that the Gs subtype
activates adenylate cyclase, thus increasing intracellular
cAMP, a secondary messenger that signals through activa-
tionofPKAorexchangeproteins activatedbycAMP(32). In
contrast, activation of the Gi subtype inhibits adenylate cy-
clase and suppresses signaling of the cAMP/PKA pathway.
The Gq subtype activates PLC, which increases the second
messengers IP3 and diacylglycerol. Water-soluble IP3 dif-
fuses through the cytoplasm into the ER, where it binds to
and opens calcium channels, releasing calcium stores into
the cytoplasm (5, 33–35). Ionized calcium affects many
cellular processes, including activation of NADPH oxidase,
an enzyme capable of generating large amounts of super-
oxide. Having used pharmacologic approaches to study
these pathways in the retina, we acknowledge that some
Figure 5. Pharmacologic activation of a2-ARs (Gi pathway)
inhibited the glucose-induced increase in superoxide gener-
ation by 661W cells. Studies were performed as described in
the legend for Fig. 2. Lof, lofexidine; Gub, guanabenz; Brim,
brimonidine. n $ 3 for all groups.
Figure 6. Combinations of sub-
optimal doses of compounds
that act on different G protein
signaling pathways show additive
effects on superoxide inhibition
in 661W cells. Simultaneous in-
hibition of the Gq and Gs path-
ways with Dox and RO (RO-04-
6790) or inhibition of the Gi
and activation of the Gq path-
ways with Dox and Gub re-
sulted in greater suppression
of superoxide generation than
single therapies. Studies were
performed as described in the
legend for Fig. 2. n = 4–5 for all
groups.
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drugs studied here could have pleiotropic effects. Although
our previous studies indicate that the diabetes-induced in-
crease in retinal superoxide arises predominantly from ret-
inal neuronal cells (photoreceptor cells), adrenergic and
serotonin receptors occur on many cell types, so the con-
tributionof variousother retinal cell types to this superoxide
generation in diabetes requires further study.
Previous studies have shown that the Gq-regulated
pathway plays an important role in the pathogenesis of
light-induced photoreceptor cell degeneration (3, 5).
Diabetes differs from retinal degenerations in that pho-
toreceptor loss is not a reproducible ﬁnding, and this
degeneration was absent in our study. Nevertheless, Dox,
a selective a1-AR blocker, was effective in suppressing the
diabetes-induced increase in superoxide generation, ex-
pression of inﬂammatory proteins, and degeneration of
retinal capillaries. This work demonstrates that the a1-
AR/PLC/IP3/NADPH oxidase pathway plays a critical
role in diabetes-induced generation of superoxide and
the degeneration of retinal capillaries. Importantly, Dox
is already U.S. Food and Drug Administration-approved
for treating patients with benign prostatic hyperplasia
and associated hypertension or urinary retention defects.
Whether or not our tested therapies also affected anti-
oxidant enzymes is presently unknown.
Altered vascular permeability also is characteristic of di-
abetic retinopathy. In our long-term studies, neither Dox
nor Apo signiﬁcantly inhibited FITC-albumin accumula-
tion in the neural retina with the sample sizes tested [al-
though theeffect ofApowas almost signiﬁcant (P= 0.065)].
The contribution of NADPH oxidase to the retinal per-
meability defect after prolonged diabetes may be less than
after diabetes of shorter durations; shorter-term studies by
others have reported that inhibition of NADPH oxidase in
diabetes protected against increased vascular permeability
(28, 36). Moreover, catalytic subunits of NADPH oxidase
have been implicatedbecause of vascular injury in ischemic
retinopathy and retinal neovascularization, as well as in
nonocular complications of diabetes (37–40). Differences
in the duration of diabetes between our 8month study and
shorter (weeks-long) studies could have resulted in addi-
tional structural or functional changes that adversely affect
vascular permeability with increasing duration of diabetes.
Nevertheless, the present results suggest that conclusion of
short-term studies might not predict outcome of long-term
trials with respect to vascular permeability and suggest that
the pathogenesis of diabetes-induced degeneration of ret-
inal capillaries could differ in some respects from the
defects causing long-term changes in vascular permeability.
It is premature to conclude that the failure of the drugs
tested herein to inhibit the permeability defect limits their
potential value in patients, because therapeutic effects on
the clinical end point that matters most (macular edema/
thickening) cannot be tested in rodents, and it remains
unclearwhetherornot retinal thickening is caused solely by
a permeability defect.
Our studies show thatDoxorApohadonly a slight or no
beneﬁcial effect on diabetes-induced defects in visual
function. The ﬁnding that therapies that inhibit diabetes-
induced degeneration of retinal capillaries have little
effect on visual function was previously observed (16).
This observation is consistent with the possibility that vas-
cular and neural cells have different susceptibilities to
these therapies or that the pathogenesis of the capillary
Figure 7. Effect of therapies on retinal explants ex vivo.
Pharmacologic inhibition of the a1-AR and Gq pathways in
retinal explants decreased superoxide generation by retinas
from nondiabetic mice incubated 4 days in 30 mM glucose,
whereas inhibition of cAMP-regulated protein kinase (PKA)
failed to reduce superoxide production. Dox, doxazosin; Gub,
guanabenz; RO, RO 04-6790, a 5-HT6R antagonist; KT5720,
a PKA inhibitor. n = 4–5 for all groups.
TABLE 2. Therapeutics not affecting metabolic control over an










Non-diabetic control 8 46 6 3 153 6 25 3.3 6 0.2
Diabetic (8 mo) 8 29 6 2 519 6 34 11.1 6 0.6
Diabetic (8 mo) Dox 8 28 6 2 483 6 69 10.8 6 1.2
Diabetic (8 mo) Apo 8 26 6 3 487 6 68 11.1 6 0.5
Except for ﬁnal BW, clinical parameters were measured over the
8 month duration of diabetes as described in the Materials and
Methods section.
Figure 8. Two months of diabetes in mice (D) increased
retinal superoxide production compared with nondiabetic
mice (N) through a GPCR/PLC/IP3/Ca
2+/NADPH oxidase
signaling cascade, and inhibition of any of these downstream
steps reduced the excess superoxide generation by isolated
retina. Dox (10 mg/kg BW), U73122 (6.25 mg/kg BW), APB
(2-APB; 6.25 mg/kg BW), and Apo (36 mg/kg BW)
were injected i.p. in DMSO daily for the 2 months of diabetes.
n = 3–5 per group.
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degeneration differs in some ways from that of the visual
function defect in diabetic mice. Nevertheless, it seems
premature to conclude that this means that neither
therapy warrants further testing in diabetic patients. In-
deed, retinal edema, a major cause of visual impairment
in diabetic patients, does not even develop in most ro-
dent models of diabetic retinopathy, so the effects of
these drugs on defects in visual function and retinal
edema in patients remains to be determined.
The locationofa1-ARs in the retinacouldprovideclues as
to which cell types are involved in the effects observed. a1-
ARs reportedly aremost abundant in retinal photoreceptor
cells (41). Others reported that the distribution of a1-AR
binding sites was concentrated in the outer and inner
plexiform layers (42). In the rat retina, all 3 receptor sub-
types (2A,B,C)of thea2-ARarepresent, but are localized to
different cell types. The a2A-AR, a2B-AR, and a2C-AR are
present in cells of the ganglion cell layer and inner nuclear
layer, the neurons and glia, and the photoreceptors, re-
spectively (43). We recently reported that retinal photo-
receptors generate or regulatemost of thediabetes-induced
increase in retinal generation of superoxide (9).
b-ARs signal via the Gs pathway, leading to the accu-
mulation of cAMP. Dibutyryl-cAMP increased superoxide
even in the absence of high glucose, indicating that ele-
vating cAMP levels increases the production of superoxide
and other reactive oxygen species, as also noted in other
conditions (44). Thus, basedonourprevious studieswhich
demonstrated a strong association between the generation
of superoxideanddevelopmentofdiabetic retinopathy,we
postulated that inhibition of b-AR signaling should inhibit
this retinopathy. Steinle et al., however, demonstrated that
a b-AR agonist (isoproterenol) reduced the formation of
degenerated capillaries in diabetes, inhibited apoptosis
of cells in the ganglion cell layer, and decreased TNF-a
and inﬂammatory mediators (45–48). Additionally, b2-AR
knockout mice or mice treated the AR antagonist, pro-
pranolol, developed features similar to those of diabetic
retinopathy even in the absence of diabetes (45, 49). Thus,
these studies seem to contradict our hypothesis about the
role of cAMP (and superoxide) in the pathogenesis of di-
abetic retinopathy. It is worth noting that gene proﬁling
revealed few b-ARs in the retina compared with a-ARs (3),
raising the possibility that effects of b-AR inhibition on the
retina could be mediated systemically, as opposed to lo-
cally. This idea would not have been tested by our in vitro
studies. HTR agonists (which also signal through the Gs
pathway) similarly have been shown by others to inhibit
oxidative changes that lead to photoreceptor degenerative
diseases (10–14).
Figure 9. Daily administration of inhibitors of
a1-ARs (Dox) and NADPH oxidase (Apo) for
8 months to mice signiﬁcantly reduced diabetes-
induced increases in retinal superoxide (A),
expression of iNOS (B), and capillary degenera-
tion (C). Dox (but not Apo) signiﬁcantly inhibited
the diabetes-induced defect in contrast sensitivity
at 8 months of diabetes, but the functional effect
was modest (D). Nondiabetic, solid squares,
solid line; diabetic, solid triangles, dashed line;
diabetic+doxazosin, solid circles, thin solid line;
diabetic+apocynin, X, thin solid line. Contrast
sensitivity was determined at the same spatial
frequencies in all groups, but group means are
offset slightly to allow easier visualization of the
data. n = 5 in each group. Mean 6 SEM.
Figure 10. Diabetes of 8 months duration signiﬁcantly increased
accumulation of FITC-BSA in the inner plexiform layer of mouse
retina. FITC-albumin was injected intravenously and allowed to
circulate for 20 minutes, and then ﬂuorescence in areas of the
inner plexiform layer was quantitated from retinal cross sections.
Neither compound achieved a statistically signiﬁcant difference
from the control at 8 months of diabetes. n = 4–6.
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Activation of a2-ARs, known to signal via a Gi-mediated
pathway, inhibits adenylate cyclase activation, thus pre-
venting cAMP accumulation. Activation of these receptors
by blood pressure-lowering drugs like Gub and Lof or the
neuroprotectant, Brim, strongly reduced superoxide gen-
erationcausedby elevatedglucose in vitro. Activationof this
signaling pathway is pertinent to diabetes because treat-
ment of diabetic rats with Brim signiﬁcantly inhibited the
diabetes-induced increase in vitreo-retinal VEGF expres-
sion and blood-retinal barrier breakdown (50).
Diabetes-induced changes in signaling through GPCRs
could result from alterations in ligands presented to these
receptors, but diabetes also is known to alter the expression
of GPCRs, G proteins, and adenylate cyclase. Reduced ex-
pressionofGiproteins has been reported inplatelets, aorta,
and retina from diabetic patients or rats (51–53). Expres-
sion of Gqa and Gi proteins was altered in aortas or aortic
smooth muscle from diabetic rodents (54–56), the change
apparently caused by reactive oxygen species. Sciatic nerves
of diabetic rats evidenced subnormal adenylate cyclase ac-
tivity and increased expression of Gq, Gs, and Gi proteins
(57).Twomonthsofdiabetesorexperimental galactosemia
activated the Harvey rat sarcoma viral oncogene homolog
(H-Ras), a small-molecular-weight G protein in the retina
and retinal microvessels of diabetic rats (58).
The present results are the ﬁrst to show overactive Gq
signaling playing a causal role in the development of
diabetic retinopathy. Our results with 661W cells indicated
increasedcAMPlevels in elevatedglucose,but inhibitionof
the a1-AR by Dox did not alter cAMP in elevated glucose,
and therefore presumably Dox did not reduce the reti-
nopathy by affecting cAMP-regulated pathways. Retinal
levels of cAMP were reported to be subnormal in diabetic
rats (59), but no data were presented to show whether
those animals were also catabolic (an extreme manifesta-
tion of diabetes with little relevance to most diabetic
patients).The in vivo contributionof retinal cAMPchanges
to the observed effects of drugs in diabetic retinopathy
remains to be determined.
Experimental results described here identiﬁed a series
of intrinsically linked events in which 3 signaling pathways
mediated by GPCRs (Gs, Gi, and Gq) play important roles
in the hyperglycemia-induced generation of superoxideby
retinal cells. Whether these ﬁndings are unique to the cells
we studiedoralsopertain toother retinal cells andreceptors
that use these signaling pathways remains to be learned.
Links between different GPCR pathways with respect to
superoxide generation could stem from hyperglycemia-
induced increases incytosolicCa2+concentration,whichare
known to induce superoxide generation in other con-
ditions. The therapeutic importance of demonstrating
that GPCRs regulate retinal oxidative stress in diabetes is
suggested by our evidence that the diabetes-induced de-
generation of retinal capillaries could be inhibited by
blocking either of 2 steps in the Gq signaling pathway that
lead to superoxide generation through NADPH oxidase.
We acknowledge that NADPH oxidase is unlikely to be the
only contributor to such oxidative stress and that the path-
ogenesis of different lesions (such as capillary degeneration
or increased permeability) might differ, especially with
longer durations of diabetes.
These observations raise the possibility that important
lesions of diabetic retinopathy, and perhaps other com-
plications of diabetes, could be inhibited by therapies se-
lectively targeting a subset of GPCRs or their signaling
pathways. Moreover, because all 3 GPCR signaling path-
ways regulate superoxide generation by retinal cells, com-
binations of therapies at safe low doses that target several
GPCR signaling pathways could even inhibit diabetic reti-
nopathy without undesirable side effects. Many therapeu-
tics targeting GPCRs are already U.S. Food and Drug
Administration-approved, so this approach can be readily
tested in patients. Identifying speciﬁc drugs to advance for
patient studies will require further studies. Undesirable
side effects have been reported with at least some related
drugs. For example, AZD3783, a potent inhibitor of the
5-HT1B receptor, was neurotoxic in dogs (60). Dox was
found to be highly effective in our studies, but it also can
evidence negative side effects (61), and whether a more
selective a blocker would be safer but just as effective
remains to be determined.
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TABLE 3. Effect of Dox or Apo on diabetes-induced defects in the











2 4 0.399 6 0.009 26.9 6 0.9a
Diabetic
control
2 4 0.379 6 0.003b 21.8 6 1.3a,b
Diabetic + Dox 2 4 0.375 6 0.008b 23.1 6 0.8a,b
Diabetic + Apo 2 4 0.374 6 0.006b 23.3 6 1.0a,b
Nondiabetic 8 5 0.396 6 0.006 Fig. 9D
Diabetic
control
8 5 0.358 6 0.006b Fig. 9D
Diabetic + Dox 8 5 0.349 6 0.006b Fig. 9D
Diabetic + Apo 8 5 0.351 6 0.004b Fig. 9D
Assays were performed in vivo as described in the Materials and
Methods section. All animals were 2 months of age at initiation of
diabetes. aAt 0.064 c/d. bP , 0.01 compared with nondiabetic control.
TABLE 4. Diabetes of 8 months duration did not cause loss of retinal




Number of cell layers
in outer nuclear
layer
Nondiabetic control 8 7 11.2 6 0.7
Diabetic control 8 6 12.6 6 0.8a
Diabetic + Dox 8 7 11.6 6 0.3
Diabetic + Apo 8 7 11.9 6 0.4
aP , 0.05 compared with nondiabetic control.
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